Skip to main content
OpenTrials
Completed

NCT Number: NCT02146820

Picosecond Laser for Ttreatment of Benign Pigmented Lesions

The purpose of this study is to determine whether Pico laser is effective and safe in the treatment of benign pigmented lesions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hong Kong Dermatology and Laser Centre, Hong Kong, China

Loading trial locations.

About this study

The Investigational device is a dual wavelength laser system developed for treatment of pigmented lesions and for tattoo removal. The base unit is a GentleMax system modified to emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to 400mJ, and pulse duration of 700 ps.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has Fitzpatrick skin type I-VI
  • Has unwanted benign pigmented lesions including but not limited to solar lentigines, freckles, café au lait, melasma, New of Ota, Nevus of Ito, and hyperpigmentation, and wishes to undergo laser treatments to remove them
  • Is willing to sign an informed consent form to participate in the study
  • Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

Exclusion criteria

  • Is hypersensitive to light exposure
  • Has an active sun tan
  • Has active localized or systemic infection
  • Is taking medication(s) for which sunlight is a contraindication
  • Has a history of squamous cell carcinoma or melanoma
  • Has a history of keloid scarring
  • Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment, e.g., lack of noticeable skin flaking, skin peeling and skin surface roughness.
  • Has had a laser procedure, a peel or has used lightening creams in the area to be treated with in the past six months
  • Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
  • Is female and pregnant is currently breast feeding or planning a pregnancy during the study period
  • Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine
  • Subjects with pigmented lesions that are considered not acceptable by the study doctor or any condition that, in the study doctor's opinion, would make it unsafe to treat.

Treatment and study plan

GentleMax system

Device

Picosecond Laser System for the Treatment of Pigmented Lesions

Primary outcomes

  1. Global percentage of pigment clearance

    Time frame: 3 months post the final treatment

    Global percentage of pigment clearance evaluated by blinded observers using post treatment photographs compared to baseline photographs.

Secondary outcomes

  1. Number of Participants with Adverse Events

    Time frame: 3 months

    Adverse events will be evaluated immediately after and before each subsequent laser treatment and will be based on the incidence and severity of side effects caused by the laser treatments.

Sponsors and collaborators

Lead sponsor

Syneron Medical

Industry

Registry information

Official study title

LASER TREATMENT OF BENIGN PIGMENTED LESIONS WITH A DUAL WAVELENGTH PICOSECOND LASER

Important dates

Study start
2013
Primary completion
2015
First posted
May 26, 2014
Registry last updated
Jun 26, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.